AJG — Arthur J. Gallagher & Co.

The Street remains constructive - 19 Buy / 9 Hold / 1 Sell, consensus target $284.5 (recent-average $287.25) - and the Q2 2026 print (July 30, 2026) showed continued mid-single-digit organic growth alongside a steady bolt-on cadence (Apollo Insurance Solutions on Aug 5, 2026; W.N. Tuscano on July 21, 2026; Med James and Wilson M. Beck). But the tape has clearly turned: as of 2026-09-13 the stock had fallen 8.52% in a week and 5.93% in a month, and sits 6.83% below its 20-day and 5.69% below its 50-day SMA, even while still +15.58% over six months. Positive analyst base plus deteriorating short-term price action is why sentiment reads Neutral rather than Bullish or Bearish.

Reported revenue is accelerating hard: Q2 2026 revenue of $4.003B was +24.3% YoY (vs $3.221B), Q1 2026 $4.758B was +27.7% (vs $3.727B), Q4 2025 $3.628B was +33.6% (vs $2.716B), and Q3 2025 $3.366B was +19.9% (vs $2.807B). But a large chunk of that is acquired, not organic - stockholders' equity jumped from $12.18B to $20.15B (+65%) between 2024-09-30 and 2024-12-31 while long-term debt rose from $7.79B to $12.73B, consistent with the AssuredPartners-scale deal referenced in the brief; the brief pegs organic growth at mid-single digits. Critically, earnings are NOT tracking revenue: TTM net income through Q2 2026 was $1.569B, about 4% BELOW the $1.641B TTM through Q2 2025, and TTM EPS slipped from $6.63 to $6.04. Reported operating margin compressed - Q2 2026 operating income of $588M on $4.003B revenue is 14.7%, versus Q2 2025's $624M on $3.221B (19.4%) and Q1 2026's $1.218B on $4.758B (25.6%). Some of that is textbook seasonality (Q4 is always weakest - Q4 2025 net margin 4.2%; Q4 2023 was an outright $32.2M loss) and some is likely non-cash intangible amortization and integration charges, which is the only way to bridge GAAP TTM EPS of $6.11 to the $13.25 forward estimate. One caveat: the gross-profit line in the source data is internally inconsistent across quarters, so it should not be relied on. Bottom line: strong top line, messy and currently compressing GAAP margins, heavy Q1-weighted seasonality, and the forward estimate assumes the drag is transitional.

As of 2026-09-13 AJG screens expensive on trailing GAAP and reasonable on forward adjusted. Trailing P/E is 39.4x on $6.112 EPS versus a 5-year average P/E of 42.12x - a modest discount to its own history, not a bargain. PEG is -4.035, which is meaningless here and simply reflects that trailing EPS growth is negative. P/S is 3.919 versus a 5-year average of 4.77 (about 18% below own history), and P/B is 2.601. The number that matters is forward: at $240.32, the stock trades at ~18.1x the $13.251 next-FY estimate, toward the low end of what a low-beta (0.506) brokerage compounder normally commands and below the 20-24x typical of broker peers. The deterministic model labels this "Cheap vs. its own history" (65.2). The honest caveat: the entire cheapness case rests on the gap between GAAP ($6.11 TTM) and adjusted ($13.25 forward) EPS being closed by adding back intangible amortization and deal costs - if that add-back stops being accepted by the market, the stock is not cheap at all.

The market is valuing AJG off forward adjusted EPS (~18x), not trailing GAAP (39x) - that 117% bridge from $6.11 to $13.25 is the whole story. The practical read: the current 8.5% weekly drawdown is a multiple/sentiment event tied to the softening P&C pricing cycle and to GAAP optics, not an earnings-miss event - Q2 revenue actually came in at $4.003B, up 24% YoY. That creates a two-sided setup. If the FY2027 $13.25 estimate holds and integration charges fade on schedule, $240 is discounting a re-rating that analysts already reflect in their $284.5 target. If instead organic growth slides toward low single digits as pricing softens, or if intangible-amortization add-backs get discounted by the market, GAAP EPS stays stuck near $6 and a 39x trailing multiple is a valuation trap. Watch Q3 2026 (late October) for two things: the organic growth number and whether operating margin recovers toward the Q1 2026 25.6% level or stays near Q2's 14.7%.

Weak short-term, still intact long-term. As of 2026-09-13, RSI(14) stood at 36.83 - weak but not yet oversold (the 30 line hasn't been hit). Price was 6.83% below the 20-day SMA (~$258) and 5.69% below the 50-day (~$255), but still 2.79% ABOVE the 200-day SMA (~$234), meaning this is a short-term downtrend inside a longer-term uptrend, not a broken chart. Momentum is clearly negative on the short horizon (-8.52% 1 week, -5.93% 1 month) yet positive over 3 months (+9.89%) and 6 months (+15.58%). Entry implication: there is no bottoming signal yet, so a buyer here is catching a falling knife; the cleaner setup is either a stabilization at the ~$234 200-day line with RSI turning back above 40, or a genuine flush toward RSI 30. A decisive close below the 200-day would put the $190.75 52-week low back in play and invalidate the trend read.

• Softening P&C pricing cycle: after several years of hard-market, double-digit commercial rate increases, the market is transitioning to a softer pricing environment. This directly caps organic commission growth for brokers even when exposure units grow.
• Interest rates and fiduciary investment income: brokers earn interest on premium float before remitting to carriers, so a rate plateau or cuts trim a tailwind that has flattered earnings; any renewed rate strength would do the opposite.
• Client cost inflation in health care and liability: persistent medical, retention, and liability cost pressure is pushing corporate clients toward consulting and risk-mitigation services, supporting demand for Gallagher's advisory and benefits work.
• M&A financing conditions: AJG's growth engine depends on a steady stream of tuck-in deals; higher-for-longer funding costs or a tighter credit market slows the pipeline that has been adding ~5-7 points of annual revenue.
• Defensive rotation: with a beta of 0.506, AJG is a classic low-volatility holding - it tends to attract flows when macro uncertainty rises and to lag in strong risk-on rallies, which partly explains the recent pullback after a strong six-month run.

• Q3 2026 earnings, expected late October 2026: the key reads are organic growth rate, commentary on P&C rate velocity, and margin trajectory after Q2's 14.7% operating margin.
• AssuredPartners and bolt-on integration metrics: how quickly the large acquisition plus recent deals (Apollo Insurance Solutions, W.N. Tuscano, Med James, Wilson M. Beck) convert into margin and EPS.
• Any narrowing of the GAAP-to-adjusted EPS gap - if intangible amortization and deal charges roll off as planned, reported EPS could move sharply toward the $13.25 estimate and force a re-rating.
• AI-enabled benefits tools and the 2026 US Workforce Trends Report: early signs of whether these become incremental fee revenue or remain marketing.
• Fed rate path and fiduciary investment income: a cut cycle would trim float income; a hold or hike would preserve it.

• The soft P&C pricing cycle compressing organic commission growth, which is the single biggest swing factor for the multiple.
• Acquisition and integration risk: the balance sheet moved violently (equity +65% between 2024-09-30 and 2024-12-31; long-term debt from $7.79B to $12.73B), so an integration misstep or goodwill impairment would hit both earnings and sentiment.
• GAAP earnings quality divergence: TTM EPS fell to $6.04 from $6.63, and the accruals ratio of +0.38% means reported net income is running slightly ahead of operating cash flow - not alarming, but not a clean cash-backed earnings picture either.
• Valuation risk if adjusted-EPS estimates are cut: the trailing P/E is 39.4x, the PEG is negative, and the entire "cheap" narrative depends on the $13.25 forward number holding.
• Reporting opacity in the source data: long-term debt swings from $12.62B (Q4 2025) to $497M (Q2 2026) between quarters, making true leverage difficult to verify independently.

AJG is a genuinely high-quality, asset-light, low-beta (0.506) insurance broker with sticky fee and commission revenue, mid-single-digit organic growth, a proven bolt-on M&A machine, and $2.29B of TTM free cash flow. The problem is not the business, it is the optics and the cycle: reported revenue is growing 20-30% but that is mostly bought, GAAP EPS is actually declining, and the soft P&C pricing market is a real headwind to the organic number. At ~18x forward adjusted EPS the stock is not expensive if the adjusted-earnings story holds, but the entire valuation case rests on trusting a bridge from $6.11 GAAP TTM EPS to $13.25 forward adjusted EPS. My read: a solid, unspectacular long-term compounder at a fair-to-slightly-attractive price, best accumulated on further weakness rather than chased on this bounce attempt. Analysis, not personalized advice.

Applied a 22x fair forward P/E to the $13.251 next-FY consensus EPS estimate (22 x 13.251 = $291.52). The 22x is a modest premium to insurance-broker peers (typically 20-22x) justified by AJG's 0.506 beta, recurring commission revenue, and M&A-driven EPS growth, but a discount to its own 5-year average P/E of 42.1x because that average was set during a harder P&C pricing cycle. Cross-checked against the 5-year average P/S of 4.77 (current 3.919 applies to forward revenue per share of ~$64.93 for ~$279) and the $284.5 street consensus target; my figure intentionally sits a few dollars above consensus because I weight the residual margin recovery from the integration charges more heavily.